MedDataX Logo

Radioimmunoimaging of AL Amyloidosis

NCT ID: NCT00807872

Last Updated: 2013-09-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2008-12-31

Study Completion Date

2013-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to determine the capability of a radiolabeled amyloid-reactive monoclonal antibody to document the presence and distribution of amyloid deposits by PET/CT imaging in patients with AL amyloidosis.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

To be eligible for this study, patients must have a confirmed diagnosis of AL amyloidosis without significant cardiac (New York Heart Association class IV) disease and not be on kidney dialysis. Additionally, after testing, their blood must not contain antibodies to mouse proteins. The study requires an intravenous infusion, given over 10 minutes, of the radiolabeled antibody, followed 48 hours later by a PET/CT scan. A repeat scan is done 5 to 7 days after infusion of the antibody. A 5 ml blood specimen needs to be furnished 4 and 8 weeks after the antibody infusion.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Primary Amyloidosis

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Radioimmunoimaging AL Amyloidosis PET/CT

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

I-124 Mu 11-1F4 sterile injection

Single arm study

Group Type OTHER

124I-labeled monoclonal antibody Mu 11-1F4

Intervention Type BIOLOGICAL

Single infusion of radiolabeled antibody: 2 mCi (1 mg)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

124I-labeled monoclonal antibody Mu 11-1F4

Single infusion of radiolabeled antibody: 2 mCi (1 mg)

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

anti-amyloid radioimmunoimaging agent

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Confirmed diagnosis of AL amyloidosis

Exclusion Criteria

* New York Heart Association class IV
* patient on renal dialysis
* serum antibodies to mouse protein
Minimum Eligible Age

21 Years

Maximum Eligible Age

90 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

FDA Office of Orphan Products Development

FED

Sponsor Role collaborator

University of Tennessee

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Alan Solomon

Alan Solomon, M.D.

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Alan Solomon, MD

Role: PRINCIPAL_INVESTIGATOR

University of Tennessee Graduate School of Medicine

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University of Tennessee Medical Center

Knoxville, Tennessee, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Wall JS, Kennel SJ, Stuckey AC, Long MJ, Townsend DW, Smith GT, Wells KJ, Fu Y, Stabin MG, Weiss DT, Solomon A. Radioimmunodetection of amyloid deposits in patients with AL amyloidosis. Blood. 2010 Sep 30;116(13):2241-4. doi: 10.1182/blood-2010-03-273797. Epub 2010 Jun 3.

Reference Type DERIVED
PMID: 20522711 (View on PubMed)

Related Links

Access external resources that provide additional context or updates about the study.

http://www.amyloidosisresearchfoundation.org/

Amyloid Research Foundation

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2625

Identifier Type: -

Identifier Source: org_study_id

NCT00808847

Identifier Type: -

Identifier Source: nct_alias